Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis Approximately 60% of patients aged 12 years and older treated with ...

Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis Recommendation is based on data from two pivotal trials showing Dupixent significantly ...

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type-2 inflammation or other allergic processes in phase 3 ...

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review If approved, Dupixent would be the first and only treatment ...

Recommendation is based on data from two pivotal trials showing Dupixent significantly improved itch, skin lesions and health-related quality of life in adults with prurigo nodularis If approved ...

Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis If approved, Dupixent would be the first and only targeted medicine specifically ...

Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis If approved, Dupixent would be the first and only targeted medicine specifically ...